Daily Judi

Daily Judi: Tuesday, September 13, 2022

Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:

The Brink looks at recent advancements in the battle with cancer, using engineered CAR T-cells.

Applied Clinical Trials discusses the myths and misconceptions around digital twins in a clinical trial. Among other aspects, a digital twin may reduce the need of trial participants given placebo.

Meanwhile, BioPharma Dive examines the science behind targeting RNA molecules to fight disease, and how drugmakers may benefit.

Massachusetts-based Rubius Therapeutics is to lay off 75% of its staff and will focus on new clinical development, ending research on its two main cell therapy assets, RTX-240 and RTX-224. (Fierce Biotech)

The CNS Summit 2022 will be held on November 17–20, in Boca Raton, Florida. Created as "a community of innovators and industry leaders who are not afraid to challenge the status quo," CNS was founded in 2009 to advance clinical development, focused on collaboration and innovation. Team Judi will be there!

We hope to see you today and tomorrow, September 13-14, in Boston, for DPHARM: Disruptive Innovations to Advance Clinical Trials, walking distance from our North End headquarters.

Our Culture

“Technology and process improvements will continue to decrease our timelines on creating specifications by 50 percent or more, this year. The more we continue to improve the faster we will be.”

                    –Jamie, Trial Delivery

About Judi

Judi empowers and enhances the world's clinical trial ecosystems. Our cloud-based platform has 110,000 users across 140 countries. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 Type II certified collaboration platform.

No tags found.

Stay up-to-date with whats happening

Some sub copy covering what weekly/monthly update sand news one can expect.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.